Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
Philip H. Keiser, Michael G. Sension, Edwin DeJesus, Allan Rodriguez, Jeffrey F. Olliffe, Vanessa C. Williams, John H. Wakeford, Jerry W. Snidow, Anne D. Shachoy-Clark, Julie W. Fleming, Gary E. Pakes, Jaime E. Hernandez
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment'. Together they form a unique fingerprint.